Is ARWR or ASBP more undervalued in 2026?

CirclFi compares Arrowhead Pharmaceuticals, Inc. (ARWR) and Aspire Biopharma Holdings, Inc. (ASBP) using 13 institutional-grade valuation models. ARWR has a Quality of Company score of 7.4/10 while ASBP scores 4.6/10.

Which is a better buy — ARWR or ASBP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ARWR and ASBP valuations compare?

ARWR at $77.91 and ASBP at $5.49 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ARWR vs ASBP Valuation Comparison 2026 — Intrinsic Value Analysis

ARWR

Pharmaceutical Preparations

Arrowhead Pharmaceuticals, Inc.

Quality

7.4

out of 10

Value Trap

SAFE

Price

$77.91

Last close

Models

13/13

Active

ASBP

Pharmaceutical Preparations

Aspire Biopharma Holdings, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$5.49

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	ARWR Fair Value	ARWR Upside	ASBP Fair Value	ASBP Upside
Bayesian DCF	Intrinsic	$11.17	-85.7%	$3.94	-28.2%
Earnings Power Value	Intrinsic	$10.36	-85.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$67.16	-13.8%	$7.67	+39.7%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ARWR vs ASBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ARWR vs ASBP — Which Stock Is More Undervalued?

ARWR scores higher with a 7.4/10 quality rating vs ASBP's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Arrowhead Pharmaceuticals, Inc. (ARWR) and Aspire Biopharma Holdings, Inc. (ASBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ARWR currently trades at $77.91 with a QOC of 7.4/10, while ASBP trades at $5.49 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).